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Pharmacokinetics of varying doses of nicotinamide and tumour
radiosensitisation with carbogen and nicotinamide: clinical considerations
A. Rojas, R.J. Hodgkiss, M.R.L. Stratford, M.F. Dennis & H. Johns
CRC Gray Laboratory, Mount Vernon Hospital, Northwood, UK.
Summary Plasma concentrations, after administration of varying doses of nicotinamide, were measured in
CBA male mice using a newly-developed high performance liquid chromatography assay. In all dose groups,
peak levels were observed within the first 15 min after an i.p. administration of 0.1, 0.2, 0.3 or 0.5 mg g' of
nicotinamide. There was a clear dose-dependent increase in plasma concentration with increasing dose, with
almost a five-fold lower concentration (1.0 vs 4.91mol ml-') achieved with a dose of 0.1 mg g' compared
with 0.5 mg g ', respectively. The half-life of nicotinamide increased from 1.4 h to 2.2 h over the dose range
(P<0.01). Comparisons with previous pharmacokinetic data in humans show that clinically-relevant oral
doses of 6 and 9 g in humans give plasma levels slightly higher than those achieved at 1 h with doses of 0.1 to
0.2mgg ' in mice.
Tumour radiosensitisation with carbogen alone, and with carbogen combined with varying doses of
nicotinamide (0.05 to 0.5 mg g-), was investigated using a 10-fraction in 5 days X-ray schedule. Relative to
air-breathing mice, a statistically significant increase in sensitisation was observed with both a local tumour
control and with an in vivo/in vitro excision assay (P <0.007). With the local control assay, a trend was
observed towards lower enhancement ratios (ERs) with decreasing nicotinamide dose (from 1.85 to 1.55);
carbogen alone was almost as effective as when combined with 0.1 mg g-' of nicotinamide. With the excision
assay, ERs for carbogen combined with nicotinamide increased with decreased levels of cell survival. At a
surviving fraction of 0.02, enhancement ratios of 1.39-1.48 were obtained for carbogen plus 0.1 to 0.3 mg g
of nicotinamide. These were lower than those seen with the two higher doses of 0.4 to 0.5 mg g
(ERs= 1.63-1.69).
Although hypoxia can be a limiting factor in radiotherapy,
many of the clinical trials with oxygen and oxygen-mimetic
compounds have shown little or no effect (Dische, 1983).
Cumulative toxicity of chemical radiosensitisers, tumour
heterogeneity and the small number of patients entered into
many of the trials can explain in part the failure of most of
these to show a benefit. However, the Dahanca studies show
that if an appropriate number of well stratified patients are
included in a trial, a significant gain can be obtained with
radiosensitisers (Overgaard et al., 1991). Moreover, a meta-
analysis of all the data from randomised trials shows a
significant advantage in patients where some form ofhypoxic
manipulation was done, especially for head and neck
tumours (Overgaard, 1992). Clinical expectations with
chemical radiosensitisers were based on animal studies with
large single doses of the drug (mainly misonidazole) and
radiation, and these overestimated the gain that could be
achieved clinically. Most of the fractionated X-ray rodent
tumour data, however, indicated a decrease in radiosensitisa-
tion as the dose per fraction was decreased (Fowler &
Denekamp, 1979; Hill, 1986), and are therefore consistent
with the much reduced benefit seen in patients.
By contrast with oxygen-mimetic radiosensitisers, the com-
bination of carbogen (95%02 + 5% C02) with nicotinamide,
the amide form of vitamin B3, has been shown to be a
potent, non-toxic and preferential tumour radiosensitiser
both in single dose and fractionated X-ray regimes in mice
(Chaplin et al., 1991; Kjellen et al., 1991). It has also been
shown that the sensitising efficacy of the combination tends
to increase with fractionation and enhancement ratios of over
2 have been seen at small clinically-relevant radiation doses
per fraction (Rojas, 1992). Furthermore, a large therapeutic
gain (relative to mouse kidney, lung, gut, spinal cord and, to
a lesser degree, skin) is obtained with carbogen combined
with nicotinamide (Haustermans et al., 1992; Kjellen, et al.,
1991; Rojas, et al., unpublished). In mice, skin is under
uniform moderate hypoxia and is very responsive to vaso-
active stimuli, and therefore overestimates the degree of
radiosensitisation likely to be seen in other normal tissues
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both in mouse and man (Hendry, 1979; Stewart et al.,
1982).
Pharmacokinetic studies in human volunteers show that
plasma levels of 0.7-1.6 tmolml1' can be obtained after a
single oral dose of 6g of nicotinamide (Horsman, 1992;
Stratford et al., 1992; Horsman et al., 1993). Previous animal
studies with carbogen plus nicotinamide (CON) using frac-
tionated X-ray schedules have been performed with a nico-
tinamide dose per fraction of 0.5 mgg-', which is about 3 to
5 times higher than could safely be used in man (Green,
1970; Hawkins, 1968; Hoffer, 1971; Zackheim, 1981). There
is now an interest in using carbogen with nicotinamide in
radiotherapy (Bernier & Bartelink, 1992, pers. comm;
Laddaga, 1992, pers. comm; Littbrand, 1992, pers. comm;
Saunders & Dische, 1991, pers. comm). To predict the pos-
sible clinical gain with this approach, we determined tumour
radiosensitisation with carbogen combined with varying
doses of nicotinamide in fractionated X-ray schedules, using
both a local tumour control and an excision assay. We also
investigated plasma pharmacokinetics in mice with similar
sized doses of nicotinamide, which could then be compared
with the human pharmacokinetic studies (Horsmann et al.,
1993; Stratford et al., 1992; Stratford et al., unpublished).
Materials and methods
Adult CBA/GyfBSVS male mice were used in all these experi-
ments, which were conducted under the regulations stipulated
by the UK Animals (Scientific Procedures) Act, 1986.
Pharmacokinetic studies
Non-tumour bearing mice, 10 to 15 weeks old, were allocated
randomly to treatment groups of two animals and fed and
watered ad lib throughout the procedure. Nicotinamide
(Sigma) doses of 0.1, 0.2, 0.3 and 0.5 mgg' were used and
dissolved in saline at concentrations of 10 to 50 mgml-'. At
various times after 0.01 ml g' i.p. injection, 0.5 ml blood
samples were obtained in heparinised tubes from the mice
after decapitation and plasma was separated by centrifuga-
tion within 15 min of sampling. Plasma aliquots of 100 tl1
were stored at - 20°C prior to analysis by HPLC (high
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performance liquid chromatography) using the technique of
Stratford & Dennis (1992). Briefly, to 100 ,l of plasma was
added 20 nmol of 6-methylnicotinamide (as an internal stan-
dard) followed by 1 ml methanol. After each addition the
samples were mixed and the extract then spun. The super-
natant was dried in a centrifugal evaporator and the residue
taken up in 250pl of water. The samples were then analysed
for nicotinamide using a reverse phase ion-pairing technique.
Radiation studies
The non-immunogenic, poorly differentiated mammary
adenocarcinoma CaNT was used. 0.05 ml of a cell suspension
(-5 x 106 cellsmlh ) was injected subcutaneously into the
rear dorsum of 12 to 16 week old CBA male mice, under
Metofane anaesthesia. The animals were randomly allocated
into the different treatment groups when the tumours had
reached a geometric mean diameter of 6 to 7 mm, typically
16 to 25 days after implantation.
Radiation schedule
Two separate experiments were performed using a local
tumour control assay. Nicotinamide doses of 0.1, 0.3 and
0.5 mg g' combined with carbogen, were used in both of
these; in addition 0.2 mg g' and carbogen alone were in-
vestigated in the second experiment. An in vivo/in vitro
excision assay was carried out in conjunction with the first
local control experiment, and it also included tumours
treated with carbogen alone and carbogen combined with
0.05 and 0.4 mg g-' nicotinamide. The vitamin was dissolved
in saline prior to each irradiation session at a concentration
of 5 to 50 mg ml-1, and 0.01 ml g' was injected i.p. 60 min
prior to each fraction. A regime of ten fractions was given as
two treatments per day, in an overall time of 5 days, using an
interfraction interval of 6 h between the two fractions. In
CaNT tumours no further sparing of radiation damage is
seen when the interval is increased from 2 to 4-8 h (Rojas et
al., 1990a).
X rays were generated by a Pantak X-ray set* operating at
240 kVp and 15 mA, filtered with 0.25 mm Cu and 1.0 mm
Al to give an HVL of 1.3 mm Cu. Unanaesthetised mice were
irradiated in specially designed lead jigs which were then
enclosed in a perspex box through which air or carbogen was
flushed at a rate of 5 1 min -. Air was administered 1-2 min
and carbogen 3-5 min before and during each fraction. The
dose rate was 3.9 Gymin-', with an estimated dose fall-off
from the skin surface to the midline, in a 5 to 6 mm tumour,
of --8-10% and a maximum dose variation between the
tumours in each treatment group of <1.6%. To minimise
dose non-uniformity, the mice were rotated through 1800 at
successive treatments.
Local tumour control
After treatment, tumours were measured three times per
week with vernier calipers and allowed to regrow to a maxi-
mum geometric mean diameter of 13.5 mm, which was cal-
culated from three orthogonal measurements. Complete or
partial regressions were assessed less frequently (once or
twice a week). The absence of a palpable tumour mass at 240
days was taken as an indication of local control. All regrow-
ing tumours were included in the analysis whether or not the
regrowth endpoint was reached and locally controlled
tumours were included only if their survival was greater than
or equal to 240 days. The animals were observed for a period
of 290 days. The percentage of controlled tumours at 240
days was plotted for each group and the data fitted by logit
analysis. Six to twelve mice and twelve to twenty-four mice
per dose group were irradiated in the first and second experi-
ment, respectively.
Excision assay
The effect of in vivo treatment on the viability of cells within
CaNT tumours was assessed by an in vitro colony forming
assay on cells isolated from the tumours. Ten X-ray fractions
of 0.3-2.5 Gy per fraction were given and each dose group
included six mice. Control mice were sham irradiated with
the same schedule either in air or with carbogen combined
with 0.5 mg g' of nicotinamide. 24 h after the last dose the
animals were killed by cervical dislocation, and the tumours
aseptically excised. Each tumour was weighed before being
finely minced with scissors. The material was then stirred for
30 min at 37°C with 1 mgml-' pronase, 0.5 mg ml-' col-
lagenase and 0.5mgml-l DNAase, dissolved in growth
medium without serum, followed by neutralisation of the
pronase by adding Eagles Minimal Essential medium (MEM)
with 10% foetal calf serum (FCS). To remove the enzymes
the cells were centrifuged and resuspended in MEM + 10%
FCS; any remaining clumps were broken up by syringing
through a 19 gauge needle. This procedure has been shown
by microscopy to achieve a single cell suspension, with a cell
yield of 6.5 ± 0.6 x I07cells g-' and a mean plating efficiency
of 0.26 ± 0.02. The cells were counted with a Coulter counter
and appropriate numbers were plated onto 9 cm petri dishes
that had been prepared with a feeder layer of 2 x I05
lethally-irradiated V79 379A Chinese hamster cells in
MEM + 10% FCS. Each individual tumour was plated at
two cell densities on four dishes each, except for unirradiated
controls that were plated at one cell density on 6 dishes.
There was no consistent difference in cell yield nor in tumour
weight in the different treatment groups. All dishes were
incubated (under an atmosphere of 5% 02, 5% C02, balance
nitrogen) at 37°C for 10 days, after which the medium was
removed and the colonies were then fixed and stained with
0.2% crystal violet in 70% ethanol.
Enhancement ratios
Iso-effective doses (± 95% CL), obtained from the logit fits
to the local control probability data, were used to calculate
enhancement ratios (ERs) as the ratio of the X-ray dose in
air to the dose with the sensitiser combination at the same
level of damage. Dose response curves drawn through the
survival data (Figure 3) were obtained by fitting a third-order
polynomial equation to the logarithmically transformed sur-
viving fraction (SF)$ of each individual tumour against dose,
using non-linear least-squares regression. The parameters
obtained from the fits to each survival dose-response curve
were then used to calculate iso-effective doses (± 95% CL),
and from these, enhancement ratios at three different levels
of survival were obtained in the manner described above. The
significance of differences in the dose-modifying factors
between dose-response curves, for the different treatment
groups, was estimated by carrying out a t-test on pairs of
enhancement ratios and their respective errors.
Results
Plasma clearance after a single i.p. injection of
0.1-0.5mgg-' of nicotinamide in CBA mice is shown in
Figure 1. There was rapid absorption of the compound and
peak plasma levels occurred for all dose groups within the
first 10- 15 min. The levels achieved were dose dependent,
with a nearly five-fold lower peak concentration for
0.1 mg g- compared with 0.5 mg g-l. For all dose levels the
clearance was linear in the first 3-6 h. The fits to the data
were calculated, over the time intervals indicated in Figure 1,
using non-linear least squares regression; the apparent half-
lives are shown in Table I along with other pharmacokinetic
information. There was a trend for an increase in t1 as the
*(Pantak; Astrophysics Research Ltd. Vale Rd, Windsor, UK)
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Radiosensitisation with carbogen alone was significantly
lower in the excision assay than in the local control assay.
Our earlier experience with normobaric oxygen and carbogen
has been that larger ERs are generally seen with local tumour
control than with other assays in which less cell kill is
induced (Rojas et al., 1990a). With CON, radiosensitisation
was non-significantly less with the excision assay than that
observed with local control probability (Table II cf Table
III). With the former assay, ERs increased with increasing
level of cell kill for all 6 different sensitiser combinations.
Above 5 x 101 surviving fraction no sensitising effect was
observed. At the lower levels of cell survival radiosensitisa-
tion with this assay was similar to that seen with local
tumour control. With this assay, ERs at the TCD50 level
(dose required to control 50% of tumours) were similar to
those calculated at other levels of effect (data not shown).
Time after injection (h)
Figure 1 Plasma clearance in non-tumour bearing CBA male
mice as a function of time (two mice per time point) after a single
i.p. injection of 0.1 to 0.5mgg-' of nicotinamide. The lines
represent non-linear least square regression fits using the initial 0
to 3 time points for 0.1 mg g-' (U), 0 to 5 h for 0.2 mgg' (g)
and 0.3 mgg-' (V), and 0 to 6h for 0.5 mgg- (0).
dose of nicotinamide was increased but the difference was
significant only when comparing 0.1 mg g-' with the other
doses (P<0.01).
Figure 2 shows dose-response curves from two separate
local tumour control experiments, in mice breathing air
alone, carbogen alone, or carbogen with 0.1-0.5 mg g'
nicotinamide injected 1 h before each fraction. The responses
in all repeat schedules were remarkably similar, and there
was no significant difference in the isoeffective doses obtained
when the fits were done separately for each experiment (data
not shown). Therefore, the fits shown in Figure 2 were
obtained by pooling the data. These data show a significant
increase in tumour radiosensitisation for all four doses of
nicotinamide combined with carbogen compared with
tumours treated under air-breathing conditions
(P <0.00001). Carbogen alone was also very effective and, as
shown in d, a substantial part of the sensitising effect
observed with CON was achieved by carbogen.
Cell survival curves for tumours irradiated in air, carbogen
alone or carbogen combined with nicotinamide doses from
0.05 to 0.5mg g' are shown in Figure 3. Relative to air,
radiosensitisation was seen with all CON treatments but the
magnitude of the effect was radiation dose dependent; below
0.5 Gy per fraction sensitisation was not observed.
Nicotinamide doses of 0.05 to 0.3 mg g' all gave similar
enhancements of tumour damage and these were significantly
lower than those observed with the two highest doses tested.
Carbogen alone gave a small but significant increase in
radiosensitisation.
Tables II and III summarise the enhancement ratios for
the different combinations investigated with both assays com-
pared with treatments under air-breathing conditions.
Relative to air, all ERs were significantly different (Tables IV
and V). There was a trend towards a progressive increase in
radiosensitisation as the dose of nictotinamide was increased.
Discussion
In experimental radiotherapy, tumour radiosensitisation with
carbogen combined with nicotinamide differs from that seen
with other oxygen-mimetic radiosensitisers in that the benefit
does not decrease with fractionation. At a clinically relevant
radiation dose per fraction of 2 Gy, enhancement ratios of
1.9 and 2.1 have been observed with carbogen plus 0.5 mg g-'
of nicotinamide (Rojas, 1992). Since a large and significant
therapeutic gain has been seen in mice (Haustermans, 1992;
Kjellen et al., 1991; Rojas et al., unpublished), CON could be
a very effective and non-toxic sensitiser for use in humans. In
clinical radiotherapy however, the effectiveness of the
carbogen-nicotinamide combination will be limited by the
dose of nicotinamide that can be administered to patients, by
the ability of carbogen to increase tumour PO2, and by the
extent of normal tissue sensitisation.
Until now, all the fractionated radiation studies with CON
in rodents have been carried out with nicotinamide doses of
0.5 mg g 1, which are above those that can be realistically
achieved in man. The vitamin has been used extensively in
human dermatological and psychiatric disorders, and more
recently, in the prevention and treatment of diabetes type I
(Green, 1970; Hawkins, 1968; Hoffer, 1971; Vague et al.,
1989). Doses of up to 12g per day (- 0.17mgg' for a
70 kg man) have been administered over many months. Few
side-effects, all of which are reversible, have been reported in
the literature (Hoffer, 1971; Winter & Boyer, 1973; Zackheim
et al., 1981). Two surveys conducted in the USA reported
that the major limiting toxicity with the vitamin was liver
failure, with an incidence of one in 2000-3000 patients
(Zackheim et al., 1981). Therefore, from a drug toxicity point
of view, 6-9g (-0.09-0.13mgg-1 for a 70kg man) per
day for the duration of an accelerated or a conventional
radiotherapy regime should be feasible.
Our studies show that nicotinamide doses of 0.05 to
0.5 mg g', when combined with carbogen, significantly in-
crease the radiosensitivity of rodent CaNT tumours com-
pared with fractionated X-ray treatments under air-breathing
conditions (Figures 2 and 3). Enhancement ratios obtained
with CON (0.05-0.5 mg g-1) were significantly larger than
those seen with carbogen alone (Tables IV and V). In the
local control assay, although the ER for CON (0.1 mg g-')
Table I Plasma pharmacokinetics of varying nicotinamide (NAM) doses
Time of [Peak] [Peak] [NAM] at 1 h tt
Species Dose min Lmoll' imolml-' h (± 95% CL) Reference
Mice 0.1 mgg-' 10 1.04 0.69 1.44±0.16 These data
0.2 mg g' 10 1.81 1.23 1.95 ± 0.18
0.3 mg g 10 2.89 1.98 1.95 ± 0.18
0.5 mg g' 15 4.85 3.67 2.19 ± 0.15
Mana 6g 44-180 0.7-1.1 8.7-9.2 Stratford et al., 1992
6g 5-49 1.0-1.6 6.0-11.5 Horsman et al., 1993
aRange observed in four human volunteers.
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Figure 2 Local control probability for CaNT tumours treated with 10 fractions in 5 days in air (a: A, A), with carbogen plus
0.1 mgg' (a: 0, *), 0.2mg g (b: *), 0.3 mgg' (c: V, V), 0.5mgg' of nicotinamide (d: 0, 0), or carbogen alone (d: *).
The dashed line (b to d) represents the fit to the data for irradiations in air. Errors are 95% CL. The lines through the data were
obtained by fitting pooled data from two separate experiments (open and closed symbols).
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Figure 3 Cell survival of CaNT tumour clonogens (each point
represents a mean of six mice per dose group ± I s.e.m.) with an
in vivo/in vitro excision assay. Tumours were irradiated with a 10
fractions in 5 days schedule, in air (0), carbogen alone (A) or
carbogen combined with the indicated doses of nicotinamide
(0).
was greater than that for carbogen alone, it failed to reach
significance. Carbogen alone is an effective radiosensitiser but
its efficacy varies from one experiment to another; an ER as
low as 1.2 was seen in CaNT tumours using the same frac-
tionated regime (Kjellen et al., 1991; Rojas, 1992). By con-
trast, the combination of carbogen with nicotinamide gives
large and reproducible enhancements of tumour damage
(Rojas, 1992; these data). In mice, there is no evidence of
treatment associated toxicity with CON either in conven-
tional schedules with 30 fractions in 6 weeks or in accelerated
regimes with 20-40 fractions in 3-4 weeks (Rojas et al.,
unpublished).
In the present study nicotinamide plasma concentration in
CBA mice was linearly related to administered dose on a
mg g' basis; a similar linear relationship has also been
observed in CDF1 mice and humans (Horsman, 1992; Hors-
man et al., 1993; Stratford et al., 1992). Figure 4 shows peak
plasma levels in man compared with peak levels and levels at
1 h in rodents. A single oral dose of either 6 or 9 g of
nicotinamide in man achieved a peak concentration com-
parable with peak levels obtained in mice after an i.p.
administration of 0.1 or 0.2 mg g-', respectively (Horsman et
al., 1993; Stratford, et al., 1992; Stratford et al., unpub-
lished). With the local control assay, a decrease of about 5%
in the efficacy of CON was seen when the dose of nicotin-
amide was reduced from 0.5 to 0.3 and 0.2mgg', and a
further 10% reduction when reduced to 0.1 mg g '. Although
there was almost a three-fold difference in plasma concentra-
tion between 0.5 mg g-' and 0.2 mg g-' (Figure 4, top), only
a small further gain in local control is achieved with CON by
increasing the dose of nicotinamide above 0.2 mgg'. As
shown in Figure 4 (bottom), the change in radiosensitisation
in vivo over a range of nicotinamide plasma levels is best
fitted by an exponential rather than by a linear relationship
(the exponential fit gives a lower residual sum of errors).
Others have previously reported a similar finding for nico-
tinamide alone but at a higher drug-dose level (Horsman et
al., 1989). Relative to air breathing mice, significant sensitisa-
tion is seen with CON at nicotinamide plasma concentrations
of 0.7-1.6 iimol ml-' that are achieved in humans (Table I
cf. Figure 4). Peak plasma levels seen in man indicate that 6
and 9 g doses, if combined with carbogen, could achieve ERs
higher than those observed in mice with 0.1-0.2 mgg' of
nicotinamide (Table I; Stratford et al., unpublished).
So far all the fractionated studies in rodent tumours have
been performed with a 1 h gap between nicotinamide admini-
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Table II Enhancement ratios for carbogen alone or with varying nicotinamide
(NAM) doses relative to air-breathing mice, using a local tumour control assay
NAM Dose/fraction TCD50 (Gy) ER
(mgg') Gas (Gy) (± 95% CL) (±95% CL)
0 Air 5.5-8.6 75.28 2.34
0 Carbogen 3.7-6.8 50.78 ± 4.75 1.48 ± 0.15
0.1 Carbogen 3.2-5.5 48.43 + 3.37 1.55 ± 0.12
0.2 Carbogen 3.8-5.5 43.93 2.91 1.71 0.13
0.3 Carbogen 3.1-5.2 42.75 2.57 1.76± 0.12
0.5 Carbogen 3.0-5.1 40.65 ± 1.88 1.85 ± 0.10
Table III Enhancement ratios (± 95% CL) for carbogen alone or with varying nicotinamide (NAM)
doses relative to air-breathing mice, using an excision assay
NAM Dose/fraction ER ER ER ER
(mgg') (Gy) @ (SF= 0.10) @ (SR =0.02) @ (SF= 0.01) @ (SF= 0.003)
0 0.4-2.5 1.11 0.12 1.19 0.10
0.05 0.3-2.0 1.22 0.12 1.31 0.10
0.1 0.3-2.0 1.26 0.14 1.41 0.12 1.46 0.12
0.2 0.3-2.0 1.42±0.16 1.48±0.13 1.50±0.13
0.3 0.3-2.0 1.29±0.13 1.39±0.11 1.43±0.11
0.4 0.3-2.0 1.51 ± 0.23 1.69 0.18 1.75 ± 0.17 1.85 ± 0.18
0.5 0.3-2.0 1.40±0.16 1.63±0.14 1.70±0.14 1.82±0.15
Table IV Probability that pairs of ERs are not significantly different from each other. Local tumour
control assay; P values calculated at the TCD50 level
Carbogen Carbogen Carbogen Carbogen Carbogen
+Nam 0 +Nam 0.1 + Nam 0.2 + Nam 0.3 + Nam 0.5
P relative to air <0.00001 <0.00001 <0.00001 <0.000001 <0.00001
P relative to 0.2a 0.01 0.003 0.0001
Carbogen + Nam
Omgg-'
P relative to 0.04 0.008 0.0001
Carbogen + Nam
0.1 mg g-'
P relative to 0.3a 0.05
Carbogen + Nam
0.2mgg-'
P relative to 0.1a
Carbogen + Nam
0.3 mg g-'
Statistical significance of the differences in ERs obtained with carbogen combined with the indicated
doses of nicotinamide. Comparisons were made between pairs of ERs for all combinations of treatment
schedules.aNot significant at 0.05 level.
Table V Probability that pairs of ERs are not significantly different from each other. Excision assay: P values at SF = 0.02
Carbogen Carbogen Carbogen Carbogen Carbogen Carbogen Carbogen
+Nam 0 + Nam 0.05 + Nam 0.1 + Nam 0.2 + Nam 0.3 + Nam 0.4 + Nam 0.5
P relative to air 0.007 0.0004 <0.00001 <0.00001 <0.00001 <0.00001 <0.00001
P relative to 0.05 0.004 0.0005 <0.005 <0.00001 <0.00001
Carbogen + Nam
Omgg-'
P relative to 0.la 0.02 0.2a 0.0003 0.0003
Carbogen + Nam
0.05mgg'
P relative to 0.2a 0.6a 0.007 0.01
Carbogen + Nam
0.1 mgg-
P relative to 0.9a 0.03 0.06
Carbogen + nam
0.2 mgg-'
P relative to 0.004 0.005
Carbogen + Nam
0.3 mgg-'
P relative to 0.7a
Carbogen + Nam
0.4 mgg-'
Statistical significance of the differences in ERs obtained with carbogen combined with the indicated doses of nicotinamide. Comparisons
were made between pairs of ERs for all combinations of treatment schedules.aNot significant at 0.05 level.1120 A. ROJAS et al.
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Figure 4 a, peak plasma concentrations (U) and plasma concen-
trations at lh (0) after a single i.p. dose of 0.1 to 0.5 mggI of
nicotinamide to CBA non-tumour bearing mice. For comparison
peak plasma levels seen in four human volunteers with escalating
oral doses of 1, 2, 4 (0), 6 (A) and 9 g (O) of the vitamin are
shown (0, A: Stratford et al., 1992; O: Stratford et al., unpub-
lished). Lines are least squares fits. b, Enhancement ratios
(± 95% CL) at the TCD50 level for carbogen alone or combined
with varying doses of nicotinamide, plotted against plasma con-
centration at one hour after injection of 0, 0.1, 0.2, 0.3 and
0.5mg g' nicotinamide (A, *, *, V, *, respectively).
Included are data from Kjellen, et al., 1991 (A, 0). Lines are
linear (dot-dashed) and exponential (dashed) fits to all the
data.
stration and irradiation, which is about 30 min after peak
concentrations are observed in CaNT tumours (Stratford &
Dennis, in preparation). Previously, Horsman et al. (1989)
showed tumour sensitisation decreased with decreasing dose
of nicotinamide, and only a 10% increase in radiosensitivity
could be obtained with 0.1-0.2 mgg-'. However, by reduc-
ing the interval between injection and irradiation to 20 min,
(i.e. the time at which peak tumour levels were seen for all
dose levels), they showed that ERs with 0.1-0.2 mg g-' were
comparable to those obtained with 0.4-1.0 mg g '. This sug-
gests that concentration at the time of irradiation is the
factor that mainly determines the degree of tumour radiosen-
sitisation (Horsman et al., 1993). However, if length of
exposure to nicotinamide plays any role in tumour radiosen-
sitisation, a dose of 6 g in man could be more effective than
0.1 mg g-' in the mouse, since the half-life of the vitamin in
man is 3-8 times longer than that in rodents (Table I).
Enhancement ratios in vivo with CON reported here and at
lower doses per fraction (Rojas, 1992) are relatively high if
explained solely on the basis of complete sensitisation of
hypoxic cells, and other mechanisms (e.g. selective repair
inhibition of tumour cells) have not yet been excluded.
Although no evidence of repair inhibition was seen in rodent
gut, skin and kidney (Horsman et al., 1987; Rojas et al.,
1990b; Joiner et al., unpublished), nicotinamide can change
the slopes of tumour cell survival curves, suggesting that the
radiosensitisation observed was not only due to a reduction
in the fraction of hypoxic cells (Horsman et al., 1987).
Microelectrode measurements show that carbogen is very
effective at increasing PO2 in human tumours within
2-O min of breathing the gas (Falk et al., 1992; Martin et
al., 1993), and no toxic side-effects are seen in patients even
when administered for periods of up to 2 h each day (Dische
et al., 1992; Rubin et al., 1979). Although in a large series of
patients treated with carbogen and radiotherapy there was no
evidence of increased early or late morbidity (Rubin et al.,
1979), in a small, more recent, series of patients one case of
radiation myelitis and one of skin necrosis did occur (Dische
et al., 1992); and with hyperbaric oxygen increased morbidity
was observed in cartilage, bowel and spinal cord (Dische,
1983). A palliative, pilot study of 6 fractions in 21 days in Ca
breast has shown no evidence of increased acute normal
tissue reactions in patients treated with a 6 g dose of
nicotinamide given 1.5 h before each fraction plus carbogen
given 4-O min before and during treatment (Saunders &
Dische, 1991, pers. comm). However, some degree of normal
tissue sensitisation should be anticipated with CON in
clinical radiotherapy, and spinal cord and cartilage are of
particular concern.
There is considerable interest in the clinical application of
carbogen and nicotinamide in both palliative and curative
radiotherapy. Animal data now show that very effective
radiosensitisation in clinically-relevant experimental regimes
can be obtained by combining these methods of attacking
tumour hypoxia, and mouse-man comparisons suggest that
CON could be a most effective and non-toxic radiosensitiser
for use in clinical radiotherapy. However, more laboratory
work must be done to assess further its therapeutic potential,
to identify tumour parameters that can be used as prognostic
indicators and to identify the intrinsic mechanism(s) of action
of nicotinamide.
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